ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
Clinical trials for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) explained in plain language.
Never miss a new study
Get alerted when new ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) trials appear
Sign up with your email to follow new studies for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
First human tests begin for potential Alpha-1 treatment
Disease control CompletedThis early-stage study tested the safety and how the body processes WVE-006, a potential new treatment for Alpha-1 antitrypsin deficiency. It involved 47 healthy volunteers who received either the drug or a placebo. The goal was to find safe dose levels to use in future studies w…
Matched conditions: ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
Phase: PHASE1 • Sponsor: Wave Life Sciences Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Augmented reality tries to help patients stick to breathing therapy
Symptom relief CompletedThis study looked at whether using augmented reality could help adults with Alpha-1 antitrypsin deficiency stick to their prescribed breathing exercises and daily walking. Fifty participants performed breathing techniques twice daily and aimed for 5,000 steps per day for six week…
Matched conditions: ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
Sponsor: University of Parma • Aim: Symptom relief
Last updated Apr 04, 2026 06:35 UTC